7- Référence bibliographique
[1] LUNDBERG 1., MlLATOU SMITH R. Mortality and cancer
incidence among Swedish paint industry workers with, long-term exposure to
organic solvents ' .Scandinavian journal of work, Environment and health
1998.
[2] ZULLIAN GB., BABARE R., ZAGONEL V., MONFARDINI S. Multiple
myeloma,Critical review in oncology/haematology.Guidelines for management of
cancer in the elderly 1998.
[3] AGU VU., CHRISTENSEN BL., BUFFLER PA. Geographie patterns
of multiple myeloma : racial and industrial correlates, State ofTexas,
1969-1971. J. Natl. Cancer 1980.
[4] AGU VU., CHRISTENSEN BL., BUFFLER PA. Geographie patterns
of multiple myeloma : racial and industrial correlates, State ofTexas,
1969-1971. J. Natl. Cancer 1980.
[4] GROGAN L. PLASMA CELL NEOPLASMS. In: Jaffe ES, Harris NL,
Stein H, Vardiman JW (eds.). Pathology & Genetics.. Lyon: IARC Press;
2001.
[5] GAHRTON G, DURIE BGM, SAMSON DM. Multiple Myeloma and
Related Disorders. Oxford University Press 2004.
[6] BERENSON JAMES R. Biology and Management of Multiple
Myeloma. Humana Press. 2004.
[7] SANKALE M., FRAMENT V., DIOUf S.La maladie de KAHLER dans
un service de médecine générale 1999 .
[8] OSSENT JC., WINKEL CN. Multiple myeloma in the
Afro-Caribbean population of Curacao Netherlands journal of medicine 1993 .
[9] Kyle RA. History of multiple myeloma. In: Neoplastic
Diseases of the Blood, 3rd edition.
[10] CARLEBACH M., AMIEL A. M. Multiple myeloma: monoallelic
deletions ofthe tumor suppressor genes TP 53 and RB1 in long-term follow-up.
Cancer genetics and cytogenetics 2000.
[11] BERENSON JAMES R. New Advances in the Biology and
Treatment of Myeloma Bone Disease Seminars in Hematology 2001 .
[12] CARTWRIGHT R. A., GILMAN E. A., NICHOLSON P., ALLON D.
Epidemiology of multiple myeloma in parts of England, 1984-1993 Haematological
Oncology 1999.
[13] HUREZ D. Epidémiologie des gammapathies
monoclonales .Revue du praticien 1993 .
[14] AVET-LOISEAU H., 14q32 translocations and monosomy 13
observed in monoclonal gammapathy of multiple myeloma. Intergroupe Francophone
du Myélome. Cancer Res. 1999 .
[15] HUREZ D. Epidémiologie des gammapathies
monoclonales . Revue du praticien 1993.
[16] BERGSAGEL P. L.Translocations 14q32 : trace d'un
événement oncogènique critique? : in va Workshop
international 'sur le myélome multiple Publications Med. Inter. 1995
.
[17] HAROUSEAU IL. Myélomes: physiopathologie,
diagnostic, principes du traitement Revue du praticien 1992 .
[18] BATAILLE R. 14q32 translocations and monosomy 13 Cancer
Res. 1999 .
[19] OWEN RG., DAVIS SAA .MORGAN GJ. p53 gene mutations in
multiple myeloma Molecular pathology 1997 .
[20] LOTH TS., PEROTA AL., Genetics aspects of familial
multiple myeloma Military medicine 1991.
[21] HOET P.LAUWERYS R.Cancers du système lymphatique et
hématopoïétique ( leucémies, lymphomes,
myélomes multiples) d'origine toxique professionnelle.Synthèse
des données épidémiologiques 1995 .
[22] LUNDBERG R.Mortality and cancer incidence among Swedish
paint industry workers withlong-term exposure to organic solvents 'Scandinavian
journal of work, environment and health 1998.
[23] BROWN LM., EVERETT GDHair dye use and multiple myeloma in
white men Americanjournal ofpublic health 1992 .
[24] CORREA A., JACKSON L., MOHAN Use ofhair dyes,
haematopoietic neoplasm, and lymphomas : a literature review. II. Lymphomas and
multiple myeloma Cancer investigations 2000.
[25] BOULANGER E. L'herpès virus humain 8 (HHV8).
Rôle pathogène et sensibilité aux antiviraux Annales de
biologie clinique 1999.
[26] HJAlGRIM H., FRISCH M., MELBYE M. Incidence rates of
Kaposi's sarcoma and multiple myeloma do not correlate British journal ofcancer
1998
.
[27] ZOURE D. Le myélome multiple à propos de 28
observations colligées à l'Hôpital Principal de Dakar
Thèse Médecine Dakar 1989 .
[28] DELMER A. Myélomes: physiopathoiogie, diagnostic,
traitement Impact internat 1996 .
[29] HAROUSEAU IL. Myélomes: physiopathologie,
diagnostic, principes du traitement Revue du praticien 1992 .
[30] BATAILLE R., KLEIN B. Role of interleukin-6 in multiple
myeloma
Ann. Med. Interne 1992 .
[31] Audrey Baur Chauberta, Françoise
Delacrétaza. Das Multiple Myelom , Schweiz Med Forum 2005.
[32] DURlE B. G. M.The Epidemiology, of Multiple myeloma
Seminars in Hematology 2001 .
[33] KLEIN B., BATAILLE R. Interleukine 6 et myélome
multiple chez l'homme Médecine - sciences 1991 .
[34] L PERLEMUTER , A CENAC .dictionnaire pratique de
médecine clinique .2ème Edition .MASSON.1982.
[35] NOELLE GENETET .Immunologie.4ème
edition .faure .1997.
[36] DURlE B. G. M.The Epidemiology, of Multiple myeloma
Seminars in Hematology 2001 .
[37] GREIPP PR, DURIE, BGM, ET. AL. International Staging
System for multiple myeloma. J Clin Oncol. 2005.
[38] GREIPP PR, DURIE, BGM, ET. AL. International Staging
System for multiple myeloma. J Clin Oncol. 2005.
[39] G, DURIE BGM, ET. al. Multiple Myeloma and Related
Disorders, The role of imaging in myeloma.Arnold 2004.
[40] AUDREY BAUR CHAUBERTA, FRANÇOISE DELACRETAZA. Das
Multiple Myelom , Schweiz Med Forum 2005.
[41] BATAILLE R.Plasmocytomes humains. étude clinique,
diagnostic et prognostic Encycl. Med. Chir. (Paris - France),
Hématologie, 1994.
[42] ZULIAN GB.Myélome multiple. quand et comment
faut-il traiter? Médecine et hygiène 1991.
[43] AUDREY BAUR CHAUBERTA, FRANÇOISE DELACRETAZA.Das
Multiple Myelom , Schweiz Med Forum 2005.
[44] KYLE RA, RAJKUMAR SV. Monoclonal gammopathies of
undetermined
significance. Rev Clin Exp Hematol 2002.
[45] DURlE B. G. M.The Epidemiology, of Multiple
myelomaSeminars in Hematology 2001 .
[46] FACONT.Traitement conventionnel du myélome
multiple .La revue de médecine interne 1999 .
[47] BATAlLLE R.Myélome multiple: traitements
symptomatiques et antitumoraux Encycl. Med. Chïr. (Elsevier, Paris),
Hématologie.
[48] GAHRTON G, ET AL. Allogeneic bone marrow
transplantation in multiple myeloma. Br J Haematol 1996.
[49] MALONEY DG, SAHEBI F, STOCKERL-GOLDSTEIN KE, ET AL.
Combining an allogeneic graft-vs.-myeloma effect withhigh-dose autologous
stem cell rescue in the treatment of multiple myeloma Blood 2001.
| 
